CDX model based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity

被引：0
|
作者：
Zhao, Haixin
Zhai, Fangzheng
Li, Bin
Fan, Qiangqiang
Peng, Zhengang
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [2] Genome-scale CRISPR screens identify essential genes for tumor sensitivity to NK cells
    Dufva, Olli
    Klievink, Jay
    Saeed, Khalid
    Kankainen, Matti
    Ilander, Mette
    Hannunen, Tiiina
    Lagstrom, Sonja
    Ellonen, Pekka
    Lee, Dean A.
    Mustjoki, Satu
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [3] ONCOGENIC KRAS G12C MUTATION DERIVED INHIBITOR DEVELOPMENT
    Leveles, Ibolya
    Koppany, Gergely
    Nyiri, Kinga
    Vertessy, G. Beata
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2019, 75 : E117 - E117
  • [4] KRAS G12C inhibitor combination therapies: current evidence and challenge
    Miyashita, Hirotaka
    Kato, Shumei
    Hong, David S.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] Process Research for ZG1077, a KRAS G12C Inhibitor
    Feng, Wei-Dong
    Lv, Bin-Hua
    Ye, Wei
    Wang, Cai
    Jin, Lin-Yong
    Wang, Run-Qing
    Lian, Chang-Min
    You, Kuan-Hong
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (10) : 2986 - 2996
  • [6] RESISTANT KRAS(G12C) INHIBITOR SUBCLONES EXHIBIT HETEROGENEOUS ALTERATIONS
    不详
    CANCER DISCOVERY, 2022, 12 (01) : 13 - 13
  • [7] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
  • [8] KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
    Patel, H.
    Chan, S.
    Smith, A.
    Burrows, F.
    Malik, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S146
  • [9] KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
    Nagasaka, Misako
    Li, Yiwei
    Sukari, Ammar
    Ou, Sai-Hong Ignatius
    Al-Hallak, Mohammed Najeeb
    Azmi, Asfar S.
    CANCER TREATMENT REVIEWS, 2020, 84
  • [10] GENOME-SCALE CRISPR KNOCKOUT SCREEN IDENTIFIES TIGAR AS A MODIFIER OF PARP INHIBITOR SENSITIVITY
    Fang, Pingping
    Minn, Kay
    Chien, Jeremy
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 72 - 72
12345